2011-07-07 dxcourse myppt web · 2018-05-01 · 9.3% phase 0: pre-clinical stage, development of...
TRANSCRIPT
!"#$%"%&'()*&+,%-%(./0+
10%+2($3%+*4+5678+9&+(+:9;0+<.%=($%&/%+8%>&;+
8("3%$+?@+8/03"(/0%.A+58/+<07+8'3B%&'+C#9B%"9*$*;DA+5/?9$$+E&9=%.-9'D+
-("3%$@-/03"(/0%.F"(9$@"/;9$$@/(+
+
G(/H;.*3&B+
8*3./%I+J:6A+(&B+5(B03H(.+<(9@+K5(##9&;+'0%+$(&B-/(#%+(&B+L3($9'D+*4+1G+B9(;&*-)/+.%-%(./0M+NO*=%"P%.+QRA+RSSTUI+QVRW@+
!"#$%&$'()*+,(-.$+/0*12$$NQU 5(X*.9'D+*4+-'3B9%-+%=($3()&;+
B9(;&*-)/+'%-'-+4*.+1G+(.%+%(.$D+#0(-%+-'3B9%-+*4+'%-'+(//3.(/D+
NRU 2%.D+$9Y$%+B('(+*&+#()%&'+*3'/*"%-A+/*-'Z%[%/)=%&%--+(&B+9"#(/'+9&+.%($+\*.$B+-%>&;-@+
0.5%
0.5%
0.5%34.0%
34.0%
34.0%19.4%
19.4%
19.4%33.4%
33.4%
33.4%3.2%
3.2%
3.2%1.2%
1.2%
1.2%9.3%
9.3%
9.3%Phase 0: Pre-clinical stage, development of new diagnostic tools
Phase 0: Pre-clinical stage, development of new diagnostic tools
Phase 0: Pre-clinical stage, development of new diagnostic toolsPhase I: Discriminatrory ability, normal range of values for the test
Phase I: Discriminatrory ability, normal range of values for the test
Phase I: Discriminatrory ability, normal range of values for the testPhase II: Accuracy in a case-control setting
Phase II: Accuracy in a case-control setting
Phase II: Accuracy in a case-control settingPhase IIIa: Accuracy in a population where the test is clinically indicated
Phase IIIa: Accuracy in a population where the test is clinically indicated
Phase IIIa: Accuracy in a population where the test is clinically indicatedPhase IIIb: Incremental or added value
Phase IIIb: Incremental or added value
Phase IIIb: Incremental or added valuePhase IVa: Clinical consequences of introducing the test, clinical trial or impact study
Phase IVa: Clinical consequences of introducing the test, clinical trial or impact study
Phase IVa: Clinical consequences of introducing the test, clinical trial or impact studyPhase IVb: Optimizing an existing test
Phase IVb: Optimizing an existing test
Phase IVb: Optimizing an existing testStudy design of studies evaluating markers and technologiesStudy design of studies evaluating markers and technologies
Study design of studies evaluating markers and technologies
8'3BD+7%-9;&+
• 7%-9;&+– ,%'.*-#%/)=%+(&($D-9-+*4+'%-'Z.%-3$'-+– ]*$$*\Z3#+*4+/%.'(9&+;.*3#-+– ^*&-%/3)=%$D+%&.*$$%B+#()%&'-+– _$$+.%-3$'-+(.%+#%.+#()%&'+N&*'+#%.+-("#$%`'%-'U+– 5678+(-+(&+(BBZ*&+'%-'+'*+RZa+bO+
• <.(;"()/+#0(-%+!!!+`+!2(+-'3BD+– 79(;&*-)/+3&/%.'(9&'D++– !&/.%"%&'($+=($3%+– ^*-'+#%.+/$9&9/($$D+9"#*.'(&'+*3'/*"%+– N^$9&9/($+9"#(/'U++
+• 2($3%+*4+5678+'*+'%-'+4*.+
Q@ 57, + +9&+ + +1GZ#()%&'-+R@ 8Z+1G + +9& + +1GZ-3-#%/'-++
8'3BD+8%>&;+c+<*#3$()*&+
• 340.5'6+$768.).+9$60/+:*.$;:<($– <*#3$()*& + +dSSASSS+– 1G+9&/9B%&/% + +QeR`QSSASSS+– f+P%$*\+gQ`B + +Wef+h1G+#()%&'-i+
+
• 4.=0$
– 1GZ#.%=($%&/%+ +QRe`QSSASSS+– :!2Z#.%=($%&/% +R@df+h1G+#()%&'-i+
– 57,Z#.%=($%&/% +j@jfh($$+1G+#()%&'-i+
8'3BD+<(.)/9#(&'-+c+<.*/%--+
O1^<+B9(;&*-%-+#()%&'+
1%("+.%/%9=%-+
&*)k/()*&+
O3.-%+=9-9'-+#()%&'+
1(H%-+(+-("#$%+4.*"+
#()%&'+
8D"#'*"()/+:*3-%0*$B+^*&'(/'-+
5678+
RZa+bO+8"%(.-+c+++++Q+5678+
• RSSRZRSQS+• ^(-%Z/*&'(/'+-%'3#+• ^*$$(P*.()*&+\9'0+<%.3=9(&+O1^<+• RZa+bO+-"%(.-+l+Q+5678+`+#()%&'+
63'/*"%+5%(-3.%-+
5678+4*.+57,+
5678+4*.++
8Z+1G+
63'/*"%+5%(-3.%-+
• !&/.%"%&'($+D9%$B+5678+*=%.+-"%(.+
• OO78Z+• ^*-'`(BB9)*&($+
/(-%+B%'%/'%B+
• OO757,+
• ^*-'`/(-%+B%'%/'%B+
1G+<()
%&'-+
1G+83-#%
/'-+
]*$$*\ZE#+
79B+57,+/(-%-+.%/%9=%+57,+,mn+
79B++bOZ+5678l+
/(-%-+.%/%9=%+,mn+
?%&%.($9o(P9$9'D+c+p9"9'()*&-++
• 8'3BD+#*#3$()*&+– _B3$'+#3$"*&(.D+1G+– p*\+:!2+– :9;0+57,+– 1G+-3-#%/'-+q+1G+0*3-%0*$B+/*&'(/'-+
• 1G+'%-)&;+– 5678+– Q+/3$'3.%`#()%&'+– 7*&%+9&+E&9=%.-9'D+$(P+
• 8*"%+(&($D-%-+&*'+k&($+• O*+B('(+*&+:!2Z-'('3-+
8'3BD+#(.)/9#(&'-+
Contaminated n=131
Missing sample or culture-result
n=72
TB-Patients included in analysis n=2,557
Contaminated n=162
TB-suspects included in analysis n=1,453
No cough n=11,128
TB-Patients n=2,629
Contacts of TB-patients identified n=12,581
Negative by culture n=964
Positive by culture n=1,431
Negative by culture n=1,203
Positive by culture n=119
1G+<()%&'-+ 1G+83-#%/'-+
,%-3$'-+Q`a+
5678+4*.+781+
_BB9)*&($+=($3%+*4+5678+*=%.+ambO+
63'/*"%+5%(-3.%-+
• !&/.%"%&'($+D9%$B+5678 +aWf+NTdf^!+RefZWafU+• OO78Z + + +ad+NTdf^!+ReZWrU+• ^*-'`(BB9)*@+/(-%+B%'%/'@ +gWTr+
• OO757, + +QS+NTdf^!+TZQRU+• ^*-'`/(-%+B%'%/'%B +gQWR+
1G+<()
%&'-+
1G+83-#%
/'-+
,%-3$'-+R`a+
]*$$*\ZE#++++++
+++++++++++++++++++
jf+($.%(BD+*&+57,+,m+
dQf+,m+\(-+&%=%.+(B(#'%B+
WRf+$*&;+B%$(D+
erf+9&9)('%B+,m+
af+B9%B+P%4*.%+,m+
RTf+-D"#'*"-+
.%-*$=%B+\`*+,m+
63'/*"%+5%(-3.%-+1G
+<()
%&'-+
1G+83-#%
/'-+
• !&/.%"%&'($+D9%$B+5678 +aWf+NTdf^!+RefZWafU+• OO7 + + +ad+NTdf^!+ReZWrU+• ^*-'`(BB9)*@+/(-%+B%'%/'@ +gWTr+
• OO7 + + +QS+NTdf^!+TZQRU+• ^*-'`/(-%+B%'%/'%B +gQWR+
,%-3$'-+a`a+
($.%(BD+jf+
&%=%.+dQf+
Q+"*&'0+af+R+"*&'0-+df+
a+"*&'0-+ef+
W+"*&'0-+Wf+
d+"*&'0-+rf+
e+"*&'0-+df+
T+"*&'0-+df+QR+"*&'0-+af+RW+"*&'0-+af+
6'0%.+WRf+
^*&/$3-9*&-+c+s3%-)*&-+NQ`aU+
+J%+&%%B+'*+;*+P%D*&B+(//3.(/D+
+
c+
+
E&B%.-'(&B+P%Y%.+\0('+0(##%&-++
P%'\%%&+(//3.(/D+(&B+#()%&'+9"#(/'+
^*&/$3-9*&-+c+s3%-)*&-+NQ`aU+
+>.$)..*$/6$?6$5.16)*$(,,0=(,1$
:*\+B9.%/'+`+9&B9.%/'+9-+'0%+$9&H+P%'\%%&++(//3.(/D+(&B+#()%&'+*3'/*"%-n+
++!+E&B%.-'(&B+P%Y%.+\0%.%+'09&;-+;%'+++ +Kp*-'+9&+1.(&-$()*&M+(&B+0*\+\%+/(&+ + + ++ +"9&9"9o%+$*--+
– B9(;&*-)/+'09&H9&;+– /$9&9/($+B%/9-9*&Z"(H9&;+– #()%&'+c+#.*=9B%.+#.%4%.%&/%-+
5678+4*.+^(-%Z]9&B9&;+
1G+-3-#%/'-+
8l+
8Z^l+t-%$4Z/3.%Bu+
,m+P%4*.%+5678+.%-3$'+p*-'+'*+4*$$*\Z3#+
G%&%k'+4.*"+5678+
8Z^Z+
O*'%I+k;3.%+4*.+9$$3-'.()=%+#3.#*-%-v+&*'+'*+-/($%+
Kp*-'+9&+1.(&-$()*&Mn+
5678+4*.+57,+
1G+<()%&'-+.%/%9=9&;+
781+
,%-9-'(&'+1G+ G%&%k'+4.*"+781+
8%&-9)=%++1G+
O*'%I+k;3.%+4*.+9$$3-'.()=%+#3.#*-%-v+&*'+'*+-/($%+
,m+&*'+"*B9k%B+
57,+,m+P%4*.%+5678+.%-3$'+p*-'+'*+4*$$*\Z3#+
Kp*-'+9&+1.(&-$()*&Mn+
^*&/$3-9*&-+c+s3%-)*&-+NR`aU+
+J%+&%%B+"*.%+-'3B9%-+`+&%\+"%(-3.%-+'*+0%$#+
#.9*.9)o%+++ + + + + +w+\0('+'%-'-++
+ + + + + +w+\0('+'%-)&;+(&B++
+ + + + + +w+\0('+;.*3#-++
.%-*3./%-+(.%+"*-'+%x/9%&'$D+-#%&'+*&+
0
50
100
150
200
250
300
0 10 20 30 40 50 60 70 80 90 100
For TB prevalence in TB-suspects of 2%
For TB prevalence in TB-suspects of 4%
For TB prevalence in TB-suspects of 8%
For TB prevalence in TB-suspects of 16%
For TB prevalence in TB-suspects of 32%
Num
ber o
f liq
uid-
cultu
res
need
ed to
dia
gnos
e
one
smea
r-ne
gativ
e/cu
lture
-pos
itive
cas
e
Proportion of TB-patients with smear-negative/culture-positive disease [%]
Data from this study
Setting with low TB- and HIV-rates
Setting with high TB- and HIV-rates
TB-prevalence in TB-suspects
2% 4% 8% 16% 32%
A
0
50
100
150
200
250
300
350
400
450
500
0 10 20 30 40 50 60
For TB-suspects
For smear-negative patients
For smear-positive patients
Num
ber o
f liq
uid-
cultu
res
need
ed
to d
iagn
ose
one
MD
RTB
cas
e
Proportion of TB-patients with MDRTB [%]
Data from this study
Setting with low TB- and HIV-rates but high MDRTB-rates
Setting with high TB- and HIV- but low MDRTB-rates
B
^*&/$3-9*&-+c+s3%-)*&-+Na`aU+
+:*\+"(&D+'%-'-+(.%+\%+\9$$9&;+'*+B*++
6,++0*\+"3/0+ggg+(.%+\%+\9$$9&;+'*+-#%&B+
+'*+B9(;&*-%+*&%+%m'.(+/(-%+*4+8Z+1G+*.+57,1Gn++c++
_.%+&%\+'%-'-+($\(D-+'0%+P%-'+3-%++*4+(=(9$(P$%+43&B-n+
• ,%-3$'I+5(&D+#()%&'-+'%-'%B+($'0*3;0+yR+\%%H-+/*3;0+!+$*\%.+D9%$B+*4+-"%(.++
• ^*&/$3-9*&I+'%-)&;+'0%+#()%&'-+\9'0+yR+\%%H-+/*3;0+-0*3$B+&*'+P%+B*&%+
• GE1I+OO7+'*+B%'%/'+(+8l+/(-%+("*&;+1GZ-3-#%/'-+\9'0+yR+\%%H-+/*3;0+\(-z+aQ+
@))68(A8.$(--=6(,B.+$/6$$<(C:)?$5.D.=$0+.$6E$.&:+A)?$/66'++
@))68(A8.$(--=6(,B.+$/6$F(+.$G:)*:)?+
>B(/$B(--.)+$5.E6=.$H.$/.+/I$+
• J0*+;%'-+(+-"%(.n+
• J0*+;%'-+(+P%Y%.+'%-'+*&+'*#`9&-'%(Bn+
• J0%.%+(.%+($$+'0%+8l+/(-%-+\%+&%=%.+-%%n+
_/H&*\$%B;%"%&'-+
!"#$%#&'()!*)+,-,!.(!*/).(0%11(2(341%#$5(65748(!9"#$5:9#.(;<=(>?4(;411@9A4(>B"87.(>?4(-%B(<5114C(-74D5B7(>B"87.(/*<(5#$(7?4(@?5B%7C(*!<E)(
Research group IFHAD: Innovation For Health And Development, a collaboration between: Peru: NGO A B PRISMA, Universidad Peruana Cayetano Heredia UK Imperial College London, London School of Hygiene & Tropical Medicine USA: Johns Hopkins Bloomberg School of Public Health, Tulane University
10(&H+D*3+4*.+D*3.+(Y%&)*&+
-("3%$@-/03"(/0%.F"(9$@"/;9$$@/(+